Zerumbone-loaded nanostructured lipid carriers: preparation, characterization, and antileukemic effect

Abstract

Zerumbone, a natural dietary lipophilic compound with low water solubility (1.296 mg/L at 25°C) was used in this investigation. The zerumbone was loaded into nanostructured lipid carriers using a hot, high-pressure homogenization technique. The physicochemical properties of the zerumbone-loaded nanostructured lipid carriers (ZER-NLC) were determined. The ZER-NLC particles had an average size of 52.68 ± 0.1 nm and a polydispersity index of 0.29 ± 0.004 µm. Transmission electron microscopy showed that the particles were spherical in shape. The zeta potential of the ZER-NLC was −25.03 ± 1.24 mV, entrapment efficiency was 99.03%, and drug loading was 7.92%. In vitro drug release of zerumbone from ZER-NLC was 46.7%, and for a pure zerumbone dispersion was 90.5% over 48 hours, following a zero equation. Using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay in human T-cell acute lymphoblastic leukemia (Jurkat) cells, the half maximal inhibitory concentration (IC 50 ) of ZER-NLC was 5.64 ± 0.38 µg/mL, and for free zerumbone was 5.39 ± 0.43 µg/mL after 72 hours of treatment. This study strongly suggests that ZER-NLC have potential as a sustainedrelease drug carrier system for the treatment of leukemia.

The effective combination therapy against human osteosarcoma: doxorubicin plus curcumin co-encapsulated lipid-coated polymeric nanoparticulate drug delivery system

“…The releases of DOX from LPNs were faster than that of CUR. The drug release from nanoparticles generally takes place by several mechanisms, including surface and bulk erosion, disintegration, diffusion, or desorption (Rahman et al, 2013). This sustained release of drug from nanoparticles is due to homogenous entrapment of the drug.…”

Targeted lung cancer therapy: preparation and optimization of transferrin-decorated nanostructured lipid carriers as novel nanomedicine for co-delivery of anticancer drugs and DNA

“…Particle size can influence the distribution of nanocarriers. 41 A small particle size is an advantage for NLC because it decreases uptake by the liver, prolongs circulation time in the blood, and improves bioavailability. 42 Small vectors are also minimally phagocytosed by macrophages, so 43 The size of Tf 5k -PTX-DNA-NLC was significantly smaller than Tf 10k -PTX-DNA-NLC (P0.05), which may cause variance in therapeutic efficiency.…”

“…Entrapment efficiency is an important parameter in the determination of drug-release characteristics; therefore, its determination is an integral part of formulation development. 41 The high EE of the NLC formulations suggested that Tf-containing ligands did not detach the drug from the NLC vectors and that the modified vectors were stable.…”

Delivery of baicalein and paclitaxel using self-assembled nanoparticles: synergistic antitumor effect in vitro and in vivo

“…Particle size is a key effect that can influence the in vivo distribution of carriers. 61 The great advantages of NPs include decreased uptake by the liver, prolonged blood circulation time, and improved bioavailability. 62,63 PDI exhibits the size distribution of NPs.…”